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Abstract
Objectives: To i) demonstrate compliance with the
Commissioning for Quality and Innovation for venous
thromboembolism risk assessment ii) to undertake root
cause analysis of Hospital Acquired Thrombosis and to
investigate its impact on quality of care.
Design: Prospective monitoring of all admissions.
Setting: Imperial College Healthcare Hospitals, London.
Participants: All Hospital Provider Spells as defined on the
NHS Data Model and Dictionary.
Main outcome measures: i) Percentage of patients
undergoing Venous Thromboembolism Risk Assessment
(VTE-RA) at and 24-hours after admission ii) root cause
analysis of Hospital Acquired Thrombosis up to 90 days
following discharge.
Results: Over a 48-month cycle 83% were overall VTE-RA
assessed with 36% in the first 12 months but with significant
improvement to 95% between April 2013 and April 2015,
achieving compliance target since April 2012 involving a
massive 633, 850 Spells over the 4 year period. We under-
took root cause analysis of all VTE episodes from April
2013 to March 2014, to ascertain Hospital Acquired
Thrombosis (HAT), we analysed 433, 174 inpatient days
and found a HAT rate of 1 per 1000 with 23% and 24%
for DVTs and PEs potentially avoidable respectively. We
further analysed VTE risk stratification (n¼ 1000) and
found 37.0% at high risk, 44.4% at medium risk and 18.6
% at low risk, indicating the need of thromboprophylaxis in
81.4% (high and medium) of whom 33.6% were excluded.
Conclusions: We achieved 95% RA compliance which has
favourably impacted on our daily practice and improved the
quality of the clinical care.
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Introduction
Venous thromboembolism (VTE) including deep vein
thrombosis (DVT) and pulmonary embolism (PE) is
a global health burden and is a signiﬁcant cause of
preventable mortality and long-term disability. VTE
is the third most common cause of cardiovascular
disease after myocardial infarction and stroke.1
VTE was mentioned on the death certiﬁcate of
approximately 17,000 deaths in England and Wales
in 2007.2 in the USA, approximately 100,000 die
annually, mostly as sudden deaths, from VTE.3
Cohen et al found that nearly three quarters of
VTE-related deaths were from HAT but only 7%
diagnosed ante-mortem; 34% were caused by
sudden fatal PE, and 59% followed undiagnosed
PE.4 The overall VTE mortality in hospitals and the
community is likely to be signiﬁcantly higher as the
condition is often missed. It is estimated that fewer
than 1 in 10 fatal pulmonary emboli are diagnosed
before death and due to a signiﬁcant decline in post-
mortems performed, VTE deaths are not identiﬁed at
post-mortem. In 2005, the House of Commons
Health Select Committee estimated an annual
25,000 HAT related fatalities in England with VTE
being the immediate cause of death in 10% of all
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hospital deaths,5,6 but the overall annual VTE
related deaths in UK is likely to be higher and is
estimated at 56,167 with the estimated death within
the major six EU countries is over 370,000 deaths
annually.4
VTE is primarily a problem in recently hospita-
lised patients being more than 100 times greater
than in the community7 and approximately half of
new VTE cases occurring during or within 90 days
from the index HPS, with many are not diagnosed
until after discharge.8,9 Moreover, up to 30% of
ﬁrst VTE event survivors have a recurrence within 5
years,10 up to 50% and 4 % develop post-thrombotic
syndrome and chronic thromboembolic pulmonary
hypertension following leg DVT11 and acute PE
respectively12 and costing approximately £640 million
per year in UK alone for treating VTE long term dis-
ability.4 The Institute for Healthcare Improvement
has been identiﬁed HAT as a fairly frequent cause
of harm (eight events per 1,000 HPS) and accounted
for one out of 17 preventable deaths13,14.
Furthermore, the NHS Safety Thermometer (NHS
ST) National Data reported a 3.5 per 1000 (0.35%)
VTE related harm in over 4 million episodes.15
The emerging picture of death, acute and chronic dis-
ability leaves no room for complacency where cost
eﬀective preventive therapy is available, demonstrat-
ing relative risk reductions up to 60% with the use of
the appropriate pharmacoprophylaxis.16,17
The number of HATs has increased despite a
heightened concerted global VTE awareness
among patient safety experts, the Agency for
Healthcare Research and Quality, DoH, NICE
and the Centres for Medicare & Medicaid
Services,18 with an average 550,000 adult HPS
had a discharge diagnosis of VTE annually in
USA alone.19 The National Quality Board and
NHS Leadership team identiﬁed VTE prevention
as an NHS clinical priority with Risk assessment
being the trigger for VTE prevention with one of
the main recommendations of the Chief Medical
Oﬃcer’s Expert Working Group Report (2007)
that all hospital patients should receive a VTE
risk assessment upon admission employing a uniﬁed
national risk assessment tool which was launched
shortly later.20 The momentum to reduce VTE
harm and death has further increased by linking
it to CQUIN payment incentive framework21 and
later root-cause analysis (RCA) on all conﬁrmed
HAT up to 90 days following discharge was intro-
duced. In this report we outline our response and
outcome of implementing VTE-RA in our organisa-
tion with 633, 850 Hospital Provider Spells (HPS)
of whom 526, 267 underwent VTE risk assessment
over a 4-year period.
Material and methods
We commenced data collection at all Imperial
Healthcare NHS Trust hospitals from April 2011
and fed it to Unify 2, the NHS portal, later than
the original date of 1 April 2010 in line with other
NHS Trusts to allow time to develop local infrastruc-
ture and/or modify existing systems which are mostly
paper-based and non- IT.
Compliance with the VTE quality indicator was
calculated by quantifying the number and the propor-
tion of all adult inpatients (18 years) who underwent
VTE-RA on admission and at 24 hours according to
the national RA tool clinical criteria. Once the data is
fed to Unify 2, the monthly compliance percentage
was automatically generated, documented but cannot
be overridden. All hospital admissions ((patients as
deﬁned on the NHS Data Model and Dictionary def-
inition of Hospital Provider Spell (patient classiﬁca-
tions 1, 2, 3, 4 &5)(elective, non-elective, maternity,
transfers from other hospitals and day case admis-
sions)) irrespective of the intended management were
included. The data extracted include regular day care
attendees were collectively included as patient cohorts,
in these cohorts, patients are deemed as not at risk of
VTE (for example haemodialysis patients and cataract
surgery) or no pharmacological or mechanical prophy-
laxis would be appropriate regardless of the risk fac-
tors. These cohorts were clearly identiﬁed and were
agreed with the Trust’s Medical Director for exclusion.
We used Electronic Discharge Communications
(EDC) system and later Cerner Millennium to elec-
tronically capture VTE RA data covering circa 4000
admissions per month including data within the
Trust’s Maternity Systems (circa 2000 spells per
month) which was extracted electronically form the
maternity dedicated IT system. Any additional data
were directly collected by VTE nurses, discussed and
veriﬁed during the C-QUIN team periodic meetings
with outstanding issues fed back to the clinical team.
For root cause analysis, cases with a VTE diagnosis
were identiﬁed from the radiology databases (V/Q
scans, CTPA scans) or Vascular Duplex laboratories
(for duplex scans) and from death certiﬁcates via
Patients Advice & Liaison Services (PALS). The RCA
data was collated from the hospital notes by the VTE
Team. Each case was then discussed with the respective
admitting consultant and reviewed by a senior RCA
site-designated member (mostly the haematologist) of
the VTE Task Force for accuracy of assigning as
HAT and adjudicated the event avoidability.
Results
In April 2011, the mean % of the data collected in the
ﬁrst quarter (Q1) was 22%. In the subsequent two
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quarters, the ﬁgure remained more or less the same
with a mean of 20% and 21% for Q2 & Q3 respect-
ively. By Q4, a routine methodology was in place to
have a handle on near full implementation and ready
data collection with Q4 at a signiﬁcant leap to a mean
of 81% but the overall Y-1 mean remained low at
36%. In the subsequent 4 quarters the data collection
targets were achieved at or above the intended target
of 90% and overall annual mean of 91%. Similarly in
year 3 (Y-3) & year 4 (Y-4) the quarter mean was
above 95% with an annual mean of 96% and
96.5% for Y-3 and Y-4 respectively in compliance
with the new elevated CQUIN target of 95%
(Table 1).
Up until March 2015 we analysed data on 633, 850
HPS of whom 526, 267 were VTE-RA on admission
and at 24-hour post-admission representing 83%
overall compliance over a 48-month and compliance
over 95% over the last 24 months. We undertook
root cause analysis following its introduction as an
additional CQUIN quality parameter for 2013–2014
with the data available including 186, 996 HPS and
433, 174 total bed days. At our trust, the overall HAT
events were lower than reported nationally at 1.07 per
1000 admissions including 0.55/1000 for DVT and
0.52/1000 for PE. The HAT rate varied between our
3 acute sites from 0.7-1.5/1000 HPS. Furthermore, we
found that events which were deemed to be avoidable
varied on the 3 sites ranging from 14-38% for DVTs
and 14–39% for PEs with overall avoidable event rate
by 23% of DVTs and 24% of PEs (Table 2) translat-
ing to an avoidable absolute rate 0.06 per 1000 HPS
translating to the prevention of further 10 VTE per
150,000 HPS per annum.
Analysis of the avoidable events showed that lack
of the VTE risk assessment in the ﬁrst place was the
main factor but performing the VTE risk assessment
but not documenting it onto the EDC was further
contributory factor. The reasons behind the variation
on the 3 diﬀerent sites are multifactorial but most
importantly the varying clinical activity portfolio
and case-mix complexity, for example one site being
a major trauma centre, major cancer surgical site and
major oncology service provider whereas one other
site harbours the hyperacute stroke services, major
neurosurgical and orthopaedic surgery as well as
Table 1. Quarterly C-QUIN compliance data.
CQUIN compliance per quarter (% completed risk assessment)
Year Q1 Q2 Q3 Q4 Annual mean
Y-1 2011 22 20 21 81 36
Y-2 2012 91 91 91 91 91
Y-3 2013 95 96 96 97 96
Y-4 2014 95 96 97 98 96.5
Table 2. HAT root cause analysis.
Number of
admissions
Number of
bed days
Number of
VTE events
VTE per 1000
Admissions % Avoidable
Avoidable rate per
1000 admissions
Site A 62,151 138, 024 DVT 34
PE 33
1.08 38%
39%
0.04
Site B 63,712 148, 874 DVT 20
PE 22
0.70 20%
14%
0.01
Site C 61,133 146, 275 DVT 49
PE 43
1.50 14%
19%
0.01
Overall 186, 996 433, 174 DVT 103
PE 98
O/A 1.07
DVT 0.55
0.52
DVT 23%
PE 24%
DVT 0.13
0.12
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tertiary vascular surgery. There are intensive care
units on three sites with maternity on two of the
three sites and coronary care on one site.
We analysed the VTE risk category of 1000 inpa-
tients (table 3) and identiﬁed a potential need of phar-
macoprophylaxis in 81.41% (high and medium) but
further risk assessment excluded 36.3% of inpatients
(all low risk, 21.6% high risk, and 21.8% medium
risk) resulting in an overall pharmacoprophylxis in
63.7% of inpatients.
Discussion
The eﬃcacy of VTE prevention using a structured
RA and administering the appropriate pharmacopro-
phylaxis is well established, is cost-eﬀective and
reduces VTE risk by up to 60%.16,17 The implemen-
tation of active strategies incorporating timely remin-
ders for VTE-RA and selecting the appropriate
prophylactic measure were shown to improve out-
come,22,23 their long term uptake, however, have
been disappointing. In the USA, it was mandated
that hospitals use formalised tools for VTE-RA and
instigate preventative measures.24,25 Eﬀective policies
to empower clinicians, improve knowledge and the
use of a robust seamless support system to embed
VTE prophylaxis into daily routine practice are man-
datory. Raising VTE awareness among patients,
carers and other healthcare professionals is another
cornerstone for long-term success.
In UK, the high-turnover of shift based junior
doctor system remains a real obstacle despite VTE
induction being a common practice. Despite abun-
dance of evidence, guidelines and protocols for
VTE prevention in developed countries, full VTE pre-
vention implementation remains an elusive objective.
The global ENDORSE study has further highlighted
this problem across 32 countries involving over
68,000 hospitalised patients of whom 55% were
non-surgical. Based on ACCP criteria, overall 52%
were judged to be at risk of VTE including 64% of
surgical and 42% of medical inpatients. Only 59% of
at risk surgical and 40% at risk medical patients
received ACCP-recommended VTE prophylaxis
conﬁrming a signiﬁcant shortfall.26 Moreover,
Bergmann et al evaluated 37,000 medical inpatient
in the same ENDORSE study27 and found risk
varied according to underlying diagnosis ranging
from 31% to 100% but ACCP-recommended
prophylaxis was underutilized with large diﬀerences
observed among countries. In the UK, the trend is
consistent with the global picture. Dr Foster
Intelligence published The Hospital Guide 2009 high-
lighting patient safety and quality and in response to
the speciﬁc question ‘What percent of patients are
risk assessed for VTE on admission’ only 31% of
trusts reported risk-assessment in more than 90% of
admissions.28
The joint DoH/NICE initiative and legislation
have led to mandatory VTE risk assessment on at
least 95% admissions since April 2013, we believe,
as from our personal experience, this has led to a
major healthcare quality improvement, the full long
term impact of which will undoubtedly emerge in the
next few years but the impact on VTE related deaths
is already manifested as highlighted by several
reports. Lester et al.29 reported on VTE risk assess-
ment using linked data from the Oﬃce of National
Statistics (ONS) and Hospital Episode Statistics
(HES), a statistically signiﬁcant reduction in deaths
(VTE is the primary cause) in hospitals achieving
90% VTE risk assessment with a relative risk (RR)
0.85 (95% CI 0.75 to 0.96; p¼ 0.011) and a further
reduction in fatal VTE with RR 0.61 (0.48 to 0.79;
p¼ 0.0002) was demonstrated for both surgical and
non-surgical patients but found no eﬀect on day case
admissions and non-fatal VTE readmissions up to 90
days.29 Furthermore, Catterick and Hunt l used data
from the Health and Social Care Information Centre
and ONS and observed a 9% reduction in the esti-
mated mean VTE-related secondary diagnosis
(p¼ 0.001). Similarly a 4% reduction in mean
30-day and 90-day VTE-related readmission rates
were observed. The observed annual VTE-related
national mortality was reduced by 9% and 8% for
two consecutive years.27 Both studies29,30 concluded
that the national quality initiative has resulted in a
signiﬁcant reduction in VTE mortality. The NHS ST
Table 3. Risk stratification and percentage received pharmacoprophylaxis.
Risk Category Number of patient (%) Number excluded (%) % received thrombopylaxis
High 370 (37.0) 80 (21.6) 78.4
Medium 444 (44.4) 97 (21.8) 78.2
Low 186 (18.6) All 0
Total 1000 (100) 363 (36.3) 63.7
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National Data Report15 has further conﬁrmed the
improved VTE risk assessment uptake on over 4 mil-
lion episodes surveyed. The proportion of patients
with a documented VTE risk assessment in the
acute settings is over 88%. The proportion of ‘at
risk’patients receiving appropriate prophylaxis in
the acute setting is approximately 82%. The propor-
tion of patients that are receiving treatment for a
clinically documented VTE event (old or new) has
reduced by 21% and for new clinically documented
VTE event in the acute setting has reduced by 27%.
The proportion of patient admissions with a VTE
coded in HES is 0.58% compared to 0.53% from
the NHS ST.15 Moreover, VTE occurrence in speciﬁc
patient group was reported by Dyer et al using HES
and identifying 0.66% (n¼ 839 patients) readmission
with VTE including 0.29% DVT and 0.37% PE
within 12 months following common urological pro-
cedures on 126,891 patients in keeping with HES and
NHS ST data.31
In our trust, implementing the VTE assessment
has been a challenging task. HAT was recorded at a
lower rate than nationally reported at 1.07 per 1000
(0.11%) admissions, including 0.55/1000 (0.06%) for
DVT and 0.52/1000 (0.05%) for PE with additional
potential 23% avoidable DVTs and 24% avoidable
PEs translating to a further reduction to 0.42/1000
and 0.40/1000 for DVT and PE respectively. Our
data compares favourably with HES data in of 5.8
per 1000 admissions. The VTE reduction in our trust
was in part triggered by a major trust policy change
in 2005 when we reported a gross underutilization of
thromboprophylaxis in hospitalised medical
patients.32 Despite lack of proper data collection
before 2011, our trust has always had a major empha-
sis on VTE prevention practice for very long time in
view of the vested academic interest in the area which
might have contributed to the lower rate of HAT. We
believe that our data is a real reﬂection of the major
advance been made in this area. Future research in
this area should focus on reﬁning risk assessment
models for VTE prevention in hospital and the
community.
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